Short description:
Cell-penetrating miniproteins
Drug notes:
5 undisclosed programs RD multiple cancers
Long description:
FogPharma is developing treatments for currently undruggable disease targets. Many drugs can be classified as monoclonal antibodies that cannot access the cell interior or as small molecules that lack specificity for interior targets. FogPharma is focusing on a new class of drugs - Helicon polypeptides - that combine the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. The polypeptides designed by FogPharma have an alpha helical shape, which confers unique drug-like properties and greater stability. FogPharma evaluates thousands of new peptides weekly in biochemical and cell-based assays to select hits to develop. FogPharma’s lead product, FOG-001, targets β-catenin, which is commonly overactive in cancer.
Jobs:
Sr. Manager, Project Management Cambridge, MA|4 days ago
Director, Clinical Supply Operations Cambridge, MA|8 days ago
Senior Director, Biology Cambridge, MA|9 days ago
Senior Director, Medicinal Chemistry - Helicon Deg... Cambridge, MA|37 days ago
Principal Associate Scientist, Pharmaceutical Scie... Cambridge, MA|50 days ago
Director, Real-World Evidence Cambridge, MA|58 days ago
Senior Compound Management Associate Cambridge, MA|66 days ago